Distribution and impact of age in patients with implantable cardioverter-defibrillators regarding early complications and 1-year clinical outcome: results from the German Device Registry.
Age
Complication
Implantable cardioverter defibrillator
Outcome
Registry
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
29
03
2020
accepted:
14
09
2020
pubmed:
24
9
2020
medline:
5
10
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
Patients receiving implantable-cardioverter-defibrillators (ICD) in clinical practice are often older or younger than in clinical trials. Whether older patients benefit from ICD-therapy in a similar way as younger patients is under debate. The objective of this study was to provide real-world data regarding outcomes with respect to age in a large cohort in the German Device Registry. Within the registry data from 50 German centers were collected between January 2007 and February 2014. Our analysis included 3239 ICD patients representing a group of young (28%; group I: < 58 years), intermediate aged (50%; group II: 58-74 years), and elderly patients (22%; group III: 75-92 years). Intergroup comparison of all groups was performed followed by individual comparison vs. group II serving as age-reference group. Procedure-related complications did not differ between all groups. Analysis of the primary endpoint, 1-year all-cause mortality, revealed an increased mortality in the elderly and a decreased mortality in the young cohort vs. the reference group II (group I 2.1%, group II 6.2%, group III 13.2%; p < 0.001). While all-cause rehospitalizations did not differ, we observed a difference in reported device revisions showing more device revisions required in younger patients (group I 8.9%, group II 6.8%, group III 4.0%; p = 0.001). One-year mortality was doubled in elderly ICD patients probably due to non-cardiac causes. These results further underpin the need for re-evaluating the primary prevention ICD indication in octo- and nonagenarians. Young patients show lower mortality rates but seem to bear higher risk of device-related complications, which highlights the need for improved measures to reduce device-related complications in the young.
Sections du résumé
BACKGROUND
BACKGROUND
Patients receiving implantable-cardioverter-defibrillators (ICD) in clinical practice are often older or younger than in clinical trials. Whether older patients benefit from ICD-therapy in a similar way as younger patients is under debate. The objective of this study was to provide real-world data regarding outcomes with respect to age in a large cohort in the German Device Registry.
METHODS
METHODS
Within the registry data from 50 German centers were collected between January 2007 and February 2014.
RESULTS
RESULTS
Our analysis included 3239 ICD patients representing a group of young (28%; group I: < 58 years), intermediate aged (50%; group II: 58-74 years), and elderly patients (22%; group III: 75-92 years). Intergroup comparison of all groups was performed followed by individual comparison vs. group II serving as age-reference group. Procedure-related complications did not differ between all groups. Analysis of the primary endpoint, 1-year all-cause mortality, revealed an increased mortality in the elderly and a decreased mortality in the young cohort vs. the reference group II (group I 2.1%, group II 6.2%, group III 13.2%; p < 0.001). While all-cause rehospitalizations did not differ, we observed a difference in reported device revisions showing more device revisions required in younger patients (group I 8.9%, group II 6.8%, group III 4.0%; p = 0.001).
CONCLUSIONS
CONCLUSIONS
One-year mortality was doubled in elderly ICD patients probably due to non-cardiac causes. These results further underpin the need for re-evaluating the primary prevention ICD indication in octo- and nonagenarians. Young patients show lower mortality rates but seem to bear higher risk of device-related complications, which highlights the need for improved measures to reduce device-related complications in the young.
Identifiants
pubmed: 32964345
doi: 10.1007/s10840-020-00876-x
pii: 10.1007/s10840-020-00876-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-93Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The task force for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology. G Ital Cardiol (Rome). 2016;17(2):108–70.
Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol. 2006;15(2):88–92.
doi: 10.1111/j.1076-7460.2006.04814.x
Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007 Jul;28(14):1746–9.
doi: 10.1093/eurheartj/ehl438
Exposito V, Rodriguez-Manero M, Gonzalez-Enriquez S, Arias MA, Sanchez-Gomez JM. Andres La Huerta a, et al. primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator in elderly patients: results of a Spanish multicentre study. Europace. 2016;18(8):1203–10.
doi: 10.1093/europace/euv337
Kobe J, Andresen D, Maier S, Stellbrink C, Kleemann T, Gonska BD, et al. Complications and 1-year benefit of cardiac resynchronization therapy in patients over 75 years of age - insights from the German device registry. Int J Cardiol. 2017;228:784–9.
doi: 10.1016/j.ijcard.2016.11.212
Duray G, Richter S, Manegold J, Israel CW, Gronefeld G, Hohnloser SH. Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. J Interv Card Electrophysiol. 2005 Dec;14(3):169–73.
doi: 10.1007/s10840-006-5200-y
Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010;153(9):592–9.
doi: 10.7326/0003-4819-153-9-201011020-00009
Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European long-QT syndrome implantable cardioverter-defibrillator (LQTS ICD) registry. Circulation. 2010 Sep 28;122(13):1272–82.
doi: 10.1161/CIRCULATIONAHA.110.950147
O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98(2):116–25.
doi: 10.1136/hrt.2010.217182
Schinkel AF. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol. 2013;6(3):562–8.
doi: 10.1161/CIRCEP.113.000392
Grimm W, Stula A, Sharkova J, Alter P, Maisch B. Outcomes of elderly recipients of implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2007;30(Suppl 1):S134–8.
pubmed: 17302690
Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ, et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol. 2007;18(8):833–8.
doi: 10.1111/j.1540-8167.2007.00857.x
Groeneveld PW. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients. LDI Issue Brief. 2008;13(6):1–4.
pubmed: 18613344
Suleiman M, Goldenberg I, Haim M, Schliamser JE, Boulos M, Ilan M, et al. Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD registry. Heart Rhythm. 2014;11(3):435–41.
doi: 10.1016/j.hrthm.2013.12.003
Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006 Jun 20;47(12):2493–7.
doi: 10.1016/j.jacc.2006.02.049
Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH. Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol. 2008;1(4):240–9.
doi: 10.1161/CIRCEP.108.777888
Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60(19):1933–9.
doi: 10.1016/j.jacc.2012.06.053
Navaneethan SD, Schold JD, Huang H, Nakhoul G, Jolly SE, Arrigain S, et al. Mortality outcomes of patients with chronic kidney disease and chronic obstructive pulmonary disease. Am J Nephrol. 2016;43(1):39–46.
doi: 10.1159/000444422
Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.
doi: 10.1056/NEJMoa1008862
Sharma A, de Souza BF, Sun JL, Thomas L, Haffner S, Holman RR, et al. Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: insights from the Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. Am Heart J. 2017;186:73–82.
doi: 10.1016/j.ahj.2016.12.011
Antiarrhythmics versus Implantable Defibrillators I. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–83.
doi: 10.1056/NEJM199711273372202
Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302.
doi: 10.1161/01.CIR.101.11.1297
Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the cardiac arrest study Hamburg (CASH). Circulation. 2000;102(7):748–54.
doi: 10.1161/01.CIR.102.7.748
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.
doi: 10.1056/NEJMoa013474
Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the multicenter automatic defibrillator implantation trial II. Circulation. 2010;122(13):1265–71.
doi: 10.1161/CIRCULATIONAHA.110.940148
Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.
doi: 10.1056/NEJMoa1608029
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.
doi: 10.1056/NEJMoa043399
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.
doi: 10.1056/NEJMoa033088
Lawin D, Israel CW, Linde C, Normand C, Dickstein K, Lober C, et al. Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT survey II. Clin Res Cardiol. 2019;109:832–44.
doi: 10.1007/s00392-019-01574-z
Shimeno K, Yoshiyama T, Abe Y, Akamatsu K, Kagawa S, Matsushita T, et al. The usefulness of right ventriculography to aid anchoring a pacing lead to the right ventricular septum. Europace. 2018;20(7):1154–60.
doi: 10.1093/europace/eux165
Bogossian H, Frommeyer G, Hochadel M, Ince H, Spitzer SG, Eckardt L, et al. Single chamber implantable cardioverter defibrillator compared to dual chamber implantable cardioverter defibrillator. Less is more! Data from the German device registry. Clin Res Cardiol. 2020;109(7):911–7.
doi: 10.1007/s00392-019-01584-x
Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474–80.
doi: 10.1161/CIRCULATIONAHA.106.663807
Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and effortless registry. J Am Coll Cardiol. 2015;65(16):1605–15.
doi: 10.1016/j.jacc.2015.02.047